“Titan Shrooms & Psychedelics” Formed to Spearhead Investments in New Frontier for Mental Health Treatments
VANCOUVER, BC, CANADA (January 23rd, 2020) – Codebase Ventures Inc. ("Codebase" or the "Company") (CSE: CODE - FSE: C5B – OTCQB: BKLLF), an investment company, announces that it has formed a wholly-owned subsidiary named Titan Shrooms & Psychedelics Inc. to spearhead its investments into the exciting, emerging market for mental health treatments using mushrooms and psychedelics.
“Mushrooms and psychedelics fit our mandate as an emerging sector with tremendous potential for those suffering from certain mental health issues, as was well documented on 60 Minutes at the end of December,”1 said Mr. Brian Keane, Director. “We are encouraged by the fact that the FDA has granted breakthrough therapy status for trials into psilocybin, the naturally occurring psychoactive compound in psychedelic mushrooms. This bodes well for innovative therapies that can help millions of people with mental health conditions ranging from treatment resistant depression to anxiety and addiction - and there are indications that the treatments could become approved at some point in 2021 as reported in Rolling Stone.”2
The Company’s subsidiary Titan Shrooms & Psychedelics will focus on identifying investment opportunities that meet with Company’s investment mandate. The Company may invest up to $2 million CAD in such opportunities. CODE is an investment company and its investments focus upon new technologies or innovative and emerging industries that have the potential to provide shareholders with significant growth.
Titan Shrooms & Psychedelics is actively seeking investment opportunities at the forefront of the mushroom and micro-dosing psychedelic healthcare sector. Codebase is not averse to taking management positions as it relates to companies in which they are investing.
2https://www.rollingstone.com/culture/culture-news/psilocybin-legal-therapy-mdma-753946/
